Safinamide is a MAO-B inhibitor used as an add-on treatment to levodopa/carbidopa for Parkinson's disease during "off" episodes. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
- Mechanism
- Curator reviewed
Safinamide is a unique molecule with multiple mechanisms of action and a very high therapeutic index. It combines potent, selective, and reversible inhibition of MAO-B with blockade of voltage-dependent Na+ and Ca2+ channels and inhibition of glutamate release. Safinamide has neuroprotective and neurorescuing effects in MPTP-treated mice, in the rat kainic acid, and in the gerbil ischemia model.
- Primary indication
- Safinamide is indicated as an add-on treatment to levodopa with or without other medicines for Parkinson’s diseaseCurator reviewed · 1 structured indication
- Formula / weight
- C17H19FN2O2 · 302.349 g/mol (avg)
- First approval
- Canada, 2019 · United States, 2017 · European Union, 2020
- Code names
- EMD-1195686
- Brand names
Resolves to
NEMGRZFTLSKBAP-LBPRGKRZSA-NSMILESC[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Safinamide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account